Welcome to OCRA’s Advocate’s Corner, a new monthly series to keep you updated on how our Advocate Leaders and policy team are working on behalf of the ovarian and gynecologic cancer community.
OCRA’s Advocates are beginning 2024 with great momentum. Here’s a look at our most impactful achievements in 2023:
Co-founded a coalition to address the current chemotherapy drug shortage and prevent future shortages.
Nearly 300 advocates from 44 states met with 380+ Congressional offices to push for important initiatives, including expanded Medicare coverage of life-saving tools like genetic testing, at OCRA’s Spring and Fall Advocacy Days.
Secured 19 new co-sponsors on targeted legislation for federal education and awareness programs as a result of our Fall Advocacy Day.
Spearheaded Dear Colleague letters in both the U.S. House and Senate calling for an increase to $50 million for the Congressionally Directed Medical Research Program’s Ovarian Cancer Research Program. The bipartisan letters were signed by almost 100 legislators.
Initiated a research project to identify health disparities within gynecologic cancer outcomes, with an initial focus on racial and geographic disparities in care.
As the largest organization advocating on behalf of patients, survivors and families of those facing ovarian and related gynecologic cancers, OCRA is committed to effecting legislative change that can prevent more diagnoses, improve outcomes, and ease the financial burden of treatment and care.
A new article from Patient Power highlights findings from a paper authored by Ovarian Cancer Research Alliance (OCRA) and Komodo Health, that reveals significant gaps in genetic testing for ovarian … Continued
Spring is here—and so is appropriations season in Washington, DC. This month has brought key developments in both the FY26 federal budget process and state-level policy action that could impact gynecologic cancer … Continued
New administrations inevitably bring changes, both big and small. The top priority of OCRA’s Policy & Advocacy team remains the same—ensuring the voices of the ovarian and gynecologic cancer community … Continued
